<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531072</url>
  </required_header>
  <id_info>
    <org_study_id>D43TW010134</org_study_id>
    <nct_id>NCT04531072</nct_id>
  </id_info>
  <brief_title>Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine</brief_title>
  <official_title>Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine in People Living With HIV Attending Lagos University Teaching Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fogarty International Center of the National Institute of Health</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NIH Office of AIDS Research (OAR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fogarty International Center of the National Institute of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case control pharmacokinetic study evaluating the effects of atazanavir-ritonavir on the&#xD;
      pharmacokinetics and toxicity of lumefantrine in people living with HIV attending APIN clinic&#xD;
      of the Lagos University Teaching Hospital&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atazanavir-ritonavir (ATVr) based antiretroviral therapy and artemether-lumefantrine (AL) are&#xD;
      commonly used drugs for the treatment of Human Immune Deficiency Virus (HIV) infection and&#xD;
      malaria respectively in Nigeria. However, both drugs interact with Cytochrome P 3A4 (CYP 3A4)&#xD;
      isoenzymes which may spawn clinically significant pharmacokinetic interactions.&#xD;
&#xD;
      The study was aimed at evaluating the effects of atazanavir-ritonavir on the pharmacokinetics&#xD;
      and toxicity of lumefantrine.&#xD;
&#xD;
      In a case control pharmacokinetic study, twenty participants who tested positive for&#xD;
      Plasmodium falciparum malaria were recruited and divided into two groups (ATVr-arm, n=10; and&#xD;
      Control-arm, n= 10). All the participants were administered with 6 doses of AL 80-480 mg&#xD;
      (Coartem). Thereafter, blood samples were collected from them at different time intervals&#xD;
      over seven days. The lumefantrine concentration in each sample was determined with&#xD;
      high-performance liquid chromatography (HPLC) and entered into WinNonlin® software to&#xD;
      determine the pharmacokinetic parameters of lumefantrine which were compared between the test&#xD;
      and control groups. Toxicity was evaluated with adverse events monitoring,&#xD;
      electrocardiography, haematological and blood chemistry tests at pre and post doses of&#xD;
      artemether-lumefantrine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arm study namely: ATVr arm and AL (Control) arm each consisting of 10 participants in a parallel study design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug exposure (Area under the curve) of lumefantrine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in drug exposure (AUC) of lumefantrine may indicate interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of lumefantrine</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change in maximum plasma concentration (Cmax) of lumefantrine may indicate interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 7 lumefantrine concentration</measure>
    <time_frame>2 weeks</time_frame>
    <description>This the plasma concentration of lumefantrine at the seventh day of commencement of the first dose. Efficacy is indicated when it is 280 ng/mL and above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>QTc-interval</measure>
    <time_frame>One week</time_frame>
    <description>Change in mean or median QTc-interval above therapeutic range at post-dose of artemether-lumefantrine indicates cardio-toxicity caused by interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>One week</time_frame>
    <description>Change in mean or median hemoglobin level above therapeutic range at post-dose of artemether-lumefantrine indicates haemotoxicity caused by interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels</measure>
    <time_frame>One week</time_frame>
    <description>Change in mean or median ALT and AST levels above therapeutic range at post-dose of artemether-lumefantrine indicates liver toxicity caused by interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine level</measure>
    <time_frame>One week</time_frame>
    <description>Change in mean or median creatinine level above therapeutic range at post-dose of artemether-lumefantrine indicates renal toxicity caused by interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Two weeks</time_frame>
    <description>Change in frequency of adverse events post-dose of artemether-lumefantrine indicates toxicity caused by interaction between atazanavir-ritonavir and lumefantrine via Cytochrome P3A4 induction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Drug Interaction</condition>
  <arm_group>
    <arm_group_label>ATVr-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 participants living with HIV and having uncomplicated Falciparum malaria were administered: Atazanavir-ritonavir (300/100 mg) one tablet once daily continuously + tenofovir-lamivudine (300/300 mg) one tablet once daily continuously and artemether-lumefantrine (80/480 mg) one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-arm (Control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 participants who were HIV negative but having uncomplicated Falciparum malaria were administered: Artemether-lumefantrine 80/480 mg, one tablet twice daily for three days at 0, 8, 24, 36, 48 and 60 hour.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy</description>
    <arm_group_label>AL-arm (Control)</arm_group_label>
    <arm_group_label>ATVr-arm</arm_group_label>
    <other_name>Coartem 80/480, P01BF01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir-ritonavir 300/100 mg</intervention_name>
    <description>Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy</description>
    <arm_group_label>ATVr-arm</arm_group_label>
    <other_name>Anzavir-R, J05AR23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or non-gravid female ≥18 years of age,&#xD;
&#xD;
          -  Informed written consent,&#xD;
&#xD;
          -  Malaria parasitaemia&#xD;
&#xD;
          -  Axillary temperature ≥37.5°C or history of fever within 24 hours before visiting the&#xD;
             clinic and with, at least, any of the following signs and symptoms of uncomplicated&#xD;
             malaria: chills, sweats, headaches, muscle aches, nausea, vomiting, diarrhoea, body&#xD;
             weakness, poor appetite and pallor.&#xD;
&#xD;
          -  Hemoglobin (Hb) ≥8 g/dl&#xD;
&#xD;
          -  Body weight ≥35 kg&#xD;
&#xD;
          -  HIV positive (ATVr arm), HIV negative (AL/control arm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe anaemia' (Haemoglobin levels &lt; 8g/dl)&#xD;
&#xD;
          -  Smokers/alcoholics and users of substances which inhibit or induce CYP3A4 iso enzymes&#xD;
&#xD;
          -  Withdrawal of consent&#xD;
&#xD;
          -  Known allergy to any of the study drugs&#xD;
&#xD;
          -  Development of complications or severe adverse effects&#xD;
&#xD;
          -  Smokers/alcoholics and users of caffeine, drugs which induce or inhibit CYP3A4 and&#xD;
             CYP2B6&#xD;
&#xD;
          -  Evidence of chronic illnesses such as diabetes, hypertension, psychiatric illnesses&#xD;
&#xD;
          -  Subject taking any drugs or having any condition known to prolong QT-intervals&#xD;
&#xD;
          -  Signs of severe malaria&#xD;
&#xD;
          -  Use of anti-tubercular drugs for at least three months prior to enrolment&#xD;
&#xD;
          -  Being on anti-malarial drugs within four weeks prior to enrolment&#xD;
&#xD;
          -  Pregnant or nursing mother.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sikiru Usman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lagos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Oreagba, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Lagos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Apin (Aids Prevention Initiatives in Nigeria) clinic, Lagos University Teaching Hospital</name>
      <address>
        <city>Suru Lere</city>
        <state>Lagos State</state>
        <zip>001</zip>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fogarty International Center of the National Institute of Health</investigator_affiliation>
    <investigator_full_name>Sikiru Olatunji Usman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug interaction, artemether-lumefantrine, atazanavir-ritonavir, LUTH</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether, Lumefantrine Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD would not be made available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

